Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The reported revenue compares to the Zacks Consensus Estimate of $7.06 billion, representing a surprise of +7.27%. The company delivered an EPS surprise of +13.77%, with the consensus EPS estimate being $1.67.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Product Sales- Veklury- U.S. $108 million versus the three-analyst average estimate of $160.11 million. The reported number represents a year-over-year change of -70.3%.
Product Sales- Oncology- Trodelvy- U.S. $247 million versus $237.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.3% change.
Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S. $185 million versus $202.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -14.4% change.
Product Sales- HIV- Symtuza-Revenue share- U.S. $112 million versus the three-analyst average estimate of $109.94 million. The reported number represents a year-over-year change of +7.7%.
Total product sales- Total: $7.54 billion versus $7.06 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change.
Revenues- Royalty contract and other revenues: $33 million versus the eight-analyst average estimate of $49.91 million. The reported number represents a year-over-year change of -26.7%.
Product Sales- Oncology- Cell Therapy- Yescarta- Total: $390 million versus $386.44 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +6% change.
Product Sales- HIV- Biktarvy- Total: $3.77 billion versus the seven-analyst average estimate of $3.46 billion. The reported number represents a year-over-year change of +21.4%.
Product Sales- HIV- Odefsey- Total: $336 million compared to the $314.11 million average estimate based on seven analysts. The reported number represents a change of -1.2% year over year.
Product Sales- HIV- Genvoya- Total: $470 million versus the seven-analyst average estimate of $482.51 million. The reported number represents a year-over-year change of -9.1%.
Product Sales- HIV- Descovy- Total: $616 million compared to the $573.59 million average estimate based on seven analysts. The reported number represents a change of +21% year over year.
Product Sales- Oncology- Trodelvy- Total: $355 million versus the seven-analyst average estimate of $281.97 million. The reported number represents a year-over-year change of +18.7%.
View all Key Company Metrics for Gilead here>>>Shares of Gilead have returned +6.2% over the past month versus the Zacks S&P 500 composite's +4.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Avino Silver Q2 Earnings & Revenues Beat Estimates, Shares Rise 1%
Shares of Avino Silver & Gold Mines Ltd. ASM gained 1% since reporting earnings per share of 6 cents for the second quarter of 2025, which beat the Zacks Consensus Estimate of 2 cents on Aug. 13. ASM had reported earnings of 3 cents in the second quarter of 2024. The improvement in earnings was aided by increased metal prices and consistent production. Including one-time items, the company reported earnings per share of 2 cents compared with 1 cent in the year-ago quarter. Avino Silver Price, Consensus and EPS Surprise Avino Silver price-consensus-eps-surprise-chart | Avino Silver Quote Avino Silver's Q2 EBITDA Soars Y/Y Avino Silver's revenues increased 47% year over year to $22 million, owing to higher sales and metal prices. The top line beat the Zacks Consensus Estimate of $18 silver equivalent sold increased 26% year over year to 676,453 company recorded cash costs of $15.11 per silver equivalent payable ounce, a 7% dip from $16.29 in the year-ago quarter. Consolidated all-in sustaining costs were $20.93 per silver payable equivalent ounce compared with $22.74 in the second quarter of Silver reported a mine-operating profit of $10 million, up 118% from $4.7 million in the year-ago quarter on higher sales. This marked the third consecutive quarter of more than $10 million in mine-operating profit. EBITDA was $7.4 million, which was 118% higher than $3.4 million in the year-ago quarter. ASM's Q2 Production Update The company's silver-equivalent production was 645,602 ounces in the second quarter of 2025, which marked a 5% increase from the second quarter of 2024. The upside was driven by record quarterly mill to the second quarter's metal-wise detailed figures, silver production slipped 3% year over year to 283,619 ounces, while gold production increased 17% to 1,774 ounces. Copper production rose 12% from the year-ago quarter to 1.46 million pounds. Avino Silver's Financial Position Avino Silver ended the second quarter with $37 million of cash in hand, higher than $27 million at the end of 2024. Cash provided by operating activities was $8.3 million compared with $1.1 million in the year-ago quarter. ASM Stock's Price Performance Shares of the company have skyrocketed 276.5% over the past year compared with the industry's 36.4% growth. Image Source: Zacks Investment Research Avino Silver's Zacks Rank Avino Silver currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Avino Silver's Peer Performances in Q2 Endeavour Silver Corporation EXK incurred an adjusted loss of 3 cents per share for the second quarter of 2025 against break-even earnings reported in the prior-year quarter. Endeavour Silver's bottom line missed the Zacks Consensus Estimate of earnings of 1 cent per Silver 's revenues improved 46% to $85 million from $58 million in the second quarter of 2024. The top line beat the Zacks Consensus Estimate of $80 Mining Company HL reported second-quarter 2025 adjusted earnings per share of 8 cents, beating the Zacks Consensus Estimate of 5 cents. Hecla Mining posted earnings of 2 cents per share in the year-ago Mining's revenues increased 23.6% year over year to $304 million in the quarter under review. The top line beat the Zacks Consensus Estimate of $274 American Silver Corp. PAAS posted second-quarter 2025 adjusted earnings per share of 43 cents, beating the Zacks Consensus Estimate of 40 cents. Pan American Silver reported earnings per share of 11 cents in the year-ago American Silver's revenues increased 18.4% year over year to $812 million in the quarter under review. The top line beat the Zacks Consensus Estimate of $782 million. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hecla Mining Company (HL) : Free Stock Analysis Report Pan American Silver Corp. (PAAS) : Free Stock Analysis Report Endeavour Silver Corporation (EXK) : Free Stock Analysis Report Avino Silver (ASM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
nCino (NCNO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
nCino (NCNO) is expected to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended July 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 26. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Zacks Consensus Estimate This company is expected to post quarterly earnings of $0.14 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $143 million, up 8% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 4.35% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for nCino? For nCino, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +3.70%. On the other hand, the stock currently carries a Zacks Rank of #1. So, this combination indicates that nCino will most likely beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that nCino would post earnings of $0.16 per share when it actually produced earnings of $0.16, delivering no surprise. Over the last four quarters, the company has beaten consensus EPS estimates two times. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. nCino appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. An Industry Player's Expected Results VNET Group (VNET), another stock in the Zacks Internet - Software industry, is expected to report earnings per share of $0.02 for the quarter ended July 2025. This estimate points to a year-over-year change of -66.7%. Revenues for the quarter are expected to be $321.33 million, up 17.1% from the year-ago quarter. The consensus EPS estimate for VNET Group has remained unchanged over the last 30 days. However, an equal Most Accurate Estimate has resulted in an Earnings ESP of 0%. This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that VNET Group will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report nCino Inc. (NCNO) : Free Stock Analysis Report VNET Group, Inc. - Unsponsored ADR (VNET) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Here's Why Array Technologies, Inc. (ARRY) is a Strong Momentum Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics. Is This 1 Momentum Stock a Screaming Buy Right Now? Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks. Array Technologies, Inc. (ARRY) Boulder, CO-based Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs for treating cancer and other high-burden diseases. The company has one marketed combination therapy in its portfolio – Braftovi (encorafenib) plus Mektovi (binimetinib). The therapy is approved for treating unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. The company is also conducting label expansion studies for the combination therapy. ARRY boasts a Momentum Style Score of A and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Shares of Array Technologies, Inc. has seen some interesting price action recently; the stock is up 53.7% over the past one week and up 23.5% over the past four weeks. And in the last one-year period, ARRY has gained 25.9%. As for the stock's trading volume, 8,222,480 shares on average were traded over the last 20 days. Momentum investors also pay close attention to a company's earnings. For ARRY, four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.05 to $0.68 per share for 2025. ARRY boasts an average earnings surprise of 19.8%. Investors should take the time to consider ARRY for their portfolios due to its solid Zacks Ranks, notable earnings metrics, and impressive Momentum and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Array Technologies, Inc. (ARRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
